Nolvadex
(tamoxifen citrate)Phase 3Small molecule
Tamoxifen is used to treat breast cancer in women and men by blocking estrogen, which can help slow or stop cancer growth. It's also used to reduce the risk of breast cancer in high-risk women.[1] Nolvadex is currently being investigated across 22 indications[3], with its most advanced program in Phase 3.[1]
Nolvadex is one of 411 small molecule programs targeting Glioma. It is currently in Phase 3.
22
Indications
108
Total Trials
7
Active Trials
410
Competitors
Pipeline
Status by Indication[3][1]
Indication
Showing 10 of 22 indications
Competition
Competitive Landscape
2828 competitors in Breast Cancer
#DrugCompanyPhaseTrials
1Nolvadex
SSan Diego Pacific Oncology & Hematology Associates
Phase 3
Tecentriq
RochePreclinical
Adriamycin
GGynecologic Oncology Group
Preclinical
Lexiscan
AstellasPreclinical
Adenocard
AstellasPreclinical
Zinecard
CChildren's Oncology Group
Preclinical
Sporanox
SSebela Pharmaceuticals Development LLC
Preclinical
Ablavar
LLantheus Medical Imaging
Preclinical
Combination NRT
UUniversity of Alabama at Birmingham
Preclinical
Maxigesic
YYonsei University
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Breast Cancer78 trials
Exemestane Compared With Tamoxifen in Treating Women With Locally Recurrent or Metastatic Breast Cancer
Completed·EEuropean Organisation for Research and Treatment of Cancer - EORTC·Phase 3·NCT00002777·342 enrolled
Chemotherapy Followed by Surgery in Treating Women With Stage II or Stage III Breast Cancer
Completed·—·Phase 2·NCT00003953·39 enrolled
Show 75 more trials
Chemotherapy and Stem Cell Transplantation in Treating Patients With Stage IIIB Breast Cancer
Completed·—·Phase 2·NCT00003042·41 enrolled
Tamoxifen Citrate in Patients With Breast Cancer
Unknown status·—·Phase 3·NCT00963209·140 enrolled
Adjuvant Stage 2-3A Breast Cancer With Positive Lymph Nodes
Completed·—·Phase 2·NCT00007904·16 enrolled
Gefitinib With or Without Tamoxifen in Treating Patients With Tamoxifen-Resistant Metastatic Breast Cancer
Completed·—·Phase 2·NCT00080743·2 enrolled
Lapatinib and Tamoxifen in Treating Patients With Advanced or Metastatic Breast Cancer
Completed·EEuropean Organisation for Research and Treatment of Cancer - EORTC·Phase 1·NCT00424164·20 enrolled
Ductal Carcinoma in Situ6 trials
Show 3 more trials
Fulvestrant or Tamoxifen in Treating Postmenopausal Women Who Are Undergoing Surgery for Ductal Carcinoma in Situ of the Breast
Unknown status·—·N/A·NCT00126464·100 enrolled
Fallopian Tube Cancer2 trials
Ovarian Cancer2 trials
Endometrial Cancer2 trials
18 more indications
Ocular Melanoma1 trial
Spinal Cord Tumor1 trial
Tamoxifen, Carboplatin, and Topotecan in Treating Patients With CNS Metastases or Recurrent Brain or Spinal Cord Tumors
Completed·—·Phase 2·NCT00541138·50 enrolled
Progesterone Receptor Positive1 trial
Glioma1 trial
Patients With Solid Tumors1 trial
Glioblastoma Multiforme1 trial
Malignant Glioma1 trial
Breast Carcinoma in Situ1 trial
Melanoma1 trial
Bladder Tumor1 trial
Evaluation the Treatment of Tamoxifen of Low/Intermediate Risk Bladder Tumors
Completed·—·Phase 2·NCT02197897·15 enrolled
Treatment1 trial
Tamoxifen in Treatment of Acute Mania
Completed·—·Phase 3·NCT00411203·66 enrolled
Recurrent Breast Carcinoma1 trial
Breast Adenocarcinoma1 trial
Breast Ductal Carcinoma in Situ1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for tamoxifen citrate. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details